Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluation and mapping of global lipid changes in schizophrenia, and upon treatment with antipsychotics. Such mapping could provide novel insights about disease mechanisms and metabolic side effects of therapies used for its treatment. We used a specialized metabolomics platform 'lipidomics' that quantifies over 300 polar and nonpolar lipid metabolites (across seven lipid classes) to evaluate global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotics. Lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n = 20), risperidone (n = 14) or aripiprazole (n = 16). Patients were recruited in two cohorts (study I, n = 27 and study II, n = 23) to permit an internal replication analyses. The change from baseline to post-treatment was then compared among the three drugs. Olanzapine and risperidone affected a much broader range of lipid classes than aripiprazole. Approximately 50 lipids tended to be increased with both risperidone and olanzapine and concentrations of triacylglycerols increased and free fatty acids decreased with both drugs but not with aripiprazole. Phosphatidylethanolamine concentrations that were suppressed in patients with schizophrenia were raised by all three drugs. Drug specific differences were also detected. A principal component analysis (PCA) identified baseline lipid alterations, which correlated with acute treatment response. A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes.
Introduction
Schizophrenia is a debilitating mental disorder characterized by psychosis, negative symptoms and neurocognitive deficits. 1 Theories of the pathophysiology underlying schizophrenia have centered on neurotransmitters and their receptors and therapeutic drug development has largely targeted dopamine, serotonin and glutamate systems. [2] [3] [4] While such therapies are proven effective in short-term trials, the vast majority of individuals discontinue treatment over time for lack of effectiveness or development of side effects and not all patients respond similarly to these medications. [5] [6] [7] [8] Over the past two decades, evidence has accrued that phospholipids, which play a critical role in the structure and function of membranes, seem to be impaired in schizophrenia. 9, 10 Neuronal cell membranes form the vesicles in which neurotransmitters are stored and through which neurotransmitters are released and hence membrane lipid changes could have a direct effect on proper neurotransmission. In addition, recent studies have highlighted a growing concern over the potential for antipsychotic drugs, especially clozapine and olanzapine, to cause metabolic adverse effects such as weight gain, hyperglycemia and hypertriglyceridemia. 11 For example, a 26-week randomized trial of 317 schizophrenic patients found that patients randomized to olanzapine were more likely to develop weight gain and total cholesterol/ triacylglycerol elevations than those randomized to aripiprazole. 12 However, to date, no study has done comprehensive analyses of global lipid effects of various atypical antipsychotics.
Metabolomics is the study of metabolism at the global level. It involves systematic study of the metabolome, the complete repertoire of small molecules present in cells, tissues or organisms.
Sophisticated metabolomic analytical platforms and informatics tools have already been developed that are making it possible to begin the process of defining signatures for disease and pathways implicated in disease process. [13] [14] [15] [16] [17] [18] [19] [20] Lipidomics is a branch of metabolomics where focus is specifically targeted on quantifying a wide range of polar and nonpolar lipid metabolites enabling a more comprehensive assessment of human lipid biochemical pathways than was previously practical. [21] [22] [23] We used this platform to map and compare global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotic drugs.
Materials and methods
The study was approved by the Institutional Review Board, and the written informed consent was obtained from the subjects or their legal guardians.
Selection criteria
Patients. We recruited 50 male or female patients (Table 1 for demographics), 18-60 years of age who met the following inclusion criteria: (1) DSM-IV criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder; (2) newly hospitalized for a psychotic exacerbation in the setting of no antipsychotic treatment for at least 3 weeks prior to admission; and (3) provided signed informed consent. We excluded patients with psychoses due to psychoactive substance abuse or an underlying medical condition. We also excluded patients who were receiving treatment for diabetes mellitus or hyperlipidemia. The subjects were recruited in two groups and samples were collected pre-and post-treatment with antipsychotics -study I consisted of 27 patients with schizophrenia (olanzapine, n = 14; risperidone, n = 9; aripiprazole, n = 4); and study II consisted of 23 new patients with schizophrenia (olanzapine, n = 6; risperidone, n = 5; aripiprazole, n = 12).
Controls. We also recruited 16 control subjects who matched the patient sample in age, gender and race. Control subjects were excluded if they or any of their first-degree relatives had a major psychiatric disorder, or if they were receiving treatment for diabetes mellitus or hyperlipidemia. All control subjects were nurses or health care technicians at the hospital.
Environment for patients
All patients remained hospitalized for the entirety of their participation. The diet available to them from the hospital cafeteria was similar to the standard diet served in homes and restaurants throughout North Carolina. They also had access to meals brought by visitors and to vending machines. Other than being required to attend group activities for 4-6 h/day, their activity level was not restricted. Smoking was available to them only during five brief smoking breaks throughout the day.
Antipsychotic treatment
The choice and dose of antipsychotic medication was based on the doctor's judgment. Olanzapine doses ranged between 10 and 30 mg/day, risperidone doses ranged between 2 and 6 mg/day and aripiprazole doses ranged between 10 and 15 mg/day. The treat- Means and standard error of patient characteristics for all patients in set 1 and set 2. *Difference between sets P < 0.05. # Difference between treatments P < 0.05.
Lipidomics in schizophrenia R Kaddurah-Daouk et al ment duration was 2-3 weeks. Average treatment time in study 1 was 21.9 days and the duration was not significantly different between risperidone and olanzapine (19 and 24 days) but was slightly shorter for aripiprazole (16 days) (P = 0.10). The mean duration of therapy was about 2 weeks for all three drugs in study II. The drug groups were otherwise generally similar in severity of disease and physical characteristics (Table 1 ). The 2-3 week duration permits the study of acute early effects.
Psychopathology assessments
Psychopathology was assessed on the Clinical Global Impressions (CGI) Scale at baseline and at the time of follow-up blood draws. Scores for the CGI Scale can range from 1 to 7, with higher scores indicating greater severity of illness. 24 An overall global change rating was also made at the time of the follow-up blood draw. The three treatment groups did not differ on the years since first treated, or psychopathology measures at the time of enrollment in the study, and all three groups showed similar patterns of treatment response (Table 1) .
Plasma sampling
All blood samples were drawn from subjects in the early morning after overnight fasting. Blood was drawn into vacutainer tubes containing sodium heparin, immediately placed on ice, and within 10 min, the blood was centrifuged and the plasma was transferred into polypropylene tubes and stored in a À301C freezer. All baseline samples were drawn prior to starting antipsychotic treatment in the study. If a patient had received a dose of an antipsychotic during the referral process (e.g. because of agitation when initially seen in a local emergency department), we waited for 2-3 days before drawing baseline plasma samples. Follow-up samples were drawn after patients had received an average 2-3 weeks of acute antipsychotic treatment.
Lipid profiling
A comprehensive assessment of plasma lipid profiles was performed (Lipomics Technologies, West Sacramento, CA), as described previously. 22 Briefly, the lipids from plasma (200 ml) were extracted with chloroform:methanol (2:1, v/v) in the presence of authentic internal standards by the method of Folch et al. 25 Individual lipid classes within the extract were separated by preparative chromatography as described by Watkins et al. 26 Briefly, for neutral lipids, TLC plates were impregnated with 1 mM EDA, pH 5.5, and washed by ascending development. Sample extracts were dried under nitrogen and spotted onto EDTA-impregnated TLC plates. For the separation of lipid classes (total PL, FFA, TAG, DAG, FC, CE), a solvent system consisting of petroleum ether/diethyl ether/acetic acid (80:20:1, by vol) was employed. The phospholipid classes are separated as described by Lutzke and Braughler 27 via high-performance liquid chromatography on an Agilent 1100 Series HPLC, with a Phenomenex Sperex 5u OH Diol column (250 Â 4.6 mm, 5 m) and a SEDEX 75 evaporative light scattering detector. Isolated lipid classes were trans-esterified in 3 N methanolic HCl in a sealed vial under a nitrogen atmosphere at 1001C for 45 min. The resulting fatty acid methyl esters were extracted with hexane containing 0.05% butylated hydroxytoluene and prepared for gas chromatography by sealing the hexane extracts under nitrogen. Fatty acid methyl esters were separated and quantified by capillary gas chromatography using a gas chromatograph (Hewlett-Packard model 6890, Wilmington, DE) equipped with a 30-m DB-225MS capillary column (J&W Scientific, Folsom, CA) and a flame-ionization detector. Quantitative measurements of fatty acids in various lipid classes were determined as nmol fatty acid/gram of plasma. Lipid classes included in this study were cholesterol esters (CE), diacylglycerols (DG), free fatty acids (FA), lysophosphatidylcholine (LY), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and triacylglycerols (TG). Lipid metabolites are identified by the lipid class and the fatty acid moiety.
Analysis of lipid pathways
Estimates of lipid synthesis enzyme activities were calculated using the product to precursor ratios for each enzyme. The following ratios were used: 18:3n6/ 18:2n6 or 24:5n6/24:4n6 for delta 6 desaturase; 20:3n6/ 18:3n6, 22:4n6/20:4n6 or 24:4n6/22:4n6 for elongase; and 20:4n6/20:3n6 for delta 5 desaturase. [28] [29] [30] The absolute value for each fatty acid metabolite was used for calculating ratios. Significant changes in such ratios were based on comparing patients and controls or upon treatment with antipsychotics.
Statistical analyses
Significant differences between pre-and post-drug treatment were assessed by paired t-tests. Evaluation of response to drug was assessed by two-way analysis of variance (ANOVA). All statistics were carried out using R with the following functions: t-test, ANOVA, prcomp and glm. 31 To address the issue of multiple comparisons and the generation of false positive results, before beginning statistical analyses, change detection was used to determine if observed signals were greater than that which could be expected by chance (noise). The chance distribution of P-values was determined by permuting the outcome groupings as described in Golub et al. 32 Briefly, P-values for the appropriate comparison were calculated for each metabolite using a Student's t-test. The metabolites were ranked by P-value from smallest to largest. The log of the rank versus the log of the P-value for each comparison of interest was plotted and is represented by a colored line. The distribution of P-values expected by chance at each rank is indicated by the shaded area. The chance distribution was determined by a Monte Carlo permutation method applied to a dataset in which the post-treatment and controls had been scaled to the same mean value and combined. Z-scores were calculated from the area under the curve (AUC) of the treatment group compared with the distribution of the AUC for the random permutations. The Z-values were used to evaluate if there was a treatment effect. For the smallest P-value that could be obtained by chance, there were at least five smaller P-values in the olanzapine group and 22 smaller P-values in the risperidone group. The distribution of P-values in the aripiprazole group was similar to the control subjects.
Heat maps were created by testing the significance of each treatment on the metabolite concentration using a paired Student's t-test. If the treatment effect was significant at alpha of 0.05, a mean percentage difference in the concentration of the metabolite induced by treatment was calculated. The heat map can be read as follows: the column headers display the fatty acid and the row headers the family of fatty acids present in each lipid class. Each cell in the heat map represents a standardized observation for a particular metabolite. Metabolites significantly increased by treatment were displayed in red, while metabolites significantly decreased by treatment were displayed in green. The brightness of each color corresponded to the magnitude of the difference in quartiles. The brighter the square, the larger the difference. For the study that involved baseline, a comparison of lipids in patients and controls was made as above, but we used unpaired Student's t-test.
Logistic regression was used to identify a set of pretreatment lipid metabolites that were related to drug response. Principal component analysis (PCA) was then used to examine how a well-selected group of lipids separates the two groups of interest: responders who had a CGI change score of 1-2 and nonresponders who had a score of 3-6. PCA is a way to explain the variance-covariance structure of a set of variables through a few linear combinations of those variables. Its general objectives are data reduction, interpretation and dealing with the highly correlated variables. PCA can reveal relationships that were not previously suspected, and allow a novel interpretation of the data.
Results
A total of 50 patients with schizophrenia were recruited participating in two studies (study I and study II, for details see Materials and methods and Table 1 for patient demographics) and the overnight fasting blood samples were collected pre-and posttreatment with antipsychotics. Also, 16 control subjects who matched the patient sample in age, gender and race were recruited for baseline studies. Average values of all lipids measured in study I and II and standard deviations are summarized in Supplementary Tables 1 and 2 .
Baseline At baseline and prior to the administration of antipsychotic medications, we compared the level of seven lipid classes between 27 patients with schizophrenia (study I) and 16 healthy controls. The heat map ( Figure 1a) shows fatty acids within the seven major lipid classes (CE, DG, FA, LY, PC, PE and TG) that are significantly different between patients with schizophrenia and controls (see statistics in Materials and methods section). The column headers display the fatty acid and the row headers the family of fatty acids present in each lipid class. Metabolites significantly higher in patients were displayed in red, while metabolites significantly lower were displayed in green.
With the exception of PE level that was significantly decreased in patients with schizophrenia, levels of all other lipid class did not differ significantly between the two groups ( Figure 1a) . Within the PE class, there were decreases in the n3, n6, and n9 fatty acid family moieties and in the fatty aldehyde (16:0, 18:0 and 18:1) moieties of plasmalogen ( Figure 1a ). There was a non-significant trend toward the decrease in PC class.
Antipsychotic effects (study I)
Olanzapine effects. The effect of olanzapine on lipids within seven major classes is shown in the heat map (Figure 1b) . Heat maps for drug effects described below were created by testing the significance of each treatment (post-treatment vs pre-treatment) on the metabolite concentration using a paired Student's t-test as described in Materials and methods. If the treatment effect was significant at alpha of 0.05, a mean percentage difference in the concentration of the metabolite induced by treatment was calculated. Metabolites significantly increased by treatment were displayed in red, while metabolites significantly decreased by treatment were displayed in green.
There were increases in PC, PE and TG (P = 0.009, 0.01 and 0.001, respectively), and decrease in FAs (P = 0.03) after olanzapine treatment (Figures 1b, 2a and b). Fatty acid changes were specific among various lipid classes following the olanzapine treatment (Figure 1b) . The concentrations of saturated and monounsaturated fatty acids in TG, PE and PC were increased. The immediate precursors and metabolites of arachidonic acid (AA, 20:4n6) were increased in TG, CE, PE and PC, but AA concentration was increased only in PE after the treatment. The ratio of AA to its precursor dihomo-gamma-linolenic acid (20:4n6/20:3n6) was significantly decreased posttreatment in CE, PE, PC and LY (P = 0.0068, 0.0041, 0.0029 and 0.0032, respectively; Supplementary Table 3 ). In addition, the immediate precursors (i.e. 20:5n3 and 22:5n3) of docosahexaenoic acid (DHA or 22:6n3) were increased following the treatment, but not the DHA concentration itself.
Risperidone effects. Risperidone treatment increased PE and PC concentrations (Figures 1b and 2d Aripiprazole effects. Minimal significant lipid changes were seen with aripiprazole ( Figure 1b) . Total PE concentrations were increased after treatment with aripiprazole (Figure 2h ), however, no other total lipid class changes were found and very little change was seen in the fatty acid concentrations (Figure 1b) .
Common effects. Taken together, there was only one metabolite (i.e. PE22:5n6) that was changed significantly by all three antipsychotics (Figure 1c ). In addition, there were increases seen with the three drugs in the phosphatidylethanolamine-polyunsaturated fatty acids (PE-PUFAs), PE-n6 fatty acid family and PE levels. There was a much larger set of lipid metabolites that was significantly and similarly changed by both risperidone and olanzapine (Figure 1b and c) , but there were other effects that were drug specific. Most notably, there were increases in the n7 and n9 FAs in olanzapine patients, decreases in these FAs in the risperidone treated patients and no changes in the aripiprazole-treated patients. Figure 1c highlights lipid metabolites that are most significantly changed in the olanzapine-treated group and the corresponding changes seen in the risperidone-and aripiprazoletreated groups.
Change-detection analysis and chance-finding assessment. We addressed the issue of chance and false positive findings since we are dealing with a large number of variables and relatively smaller number of subjects. Change detection (see statistics) was used to determine if observed signals in the lipids of the antipsychotic-treated patients were greater than that which could be expected by chance. The rankings of the P-values for drug treatment are then plotted. Both olanzapine and risperidone had more statistically significant P-values than could be expected by chance. For the smallest P-value that could be obtained by chance, there were at least five smaller P-values in the olanzapine group and 22 smaller P-values in the risperidone group (Figure 3 ). This indicated that there were true positives in the data for these groups. The distribution of P-values in the aripiprazole group was within the grade shaded area and was not different from that expected by chance.
Biochemical correlations to clinical outcome.
Baseline DG20:4n6, LY22:5n3, PE20:5n3, PEdm18: 1n7, PEdm18:1n9 lipid concentrations were found by logistic regression to correlate with early clinical response (CGI change) in a pooled analysis of all three antipsychotics. PCA was then used to examine how well the selected group of lipids separates the two groups of interest: responders who had a CGI change score of 1-2 and nonresponders who had a score of 3-6. Figure 4 shows the first two principal components plotted to demonstrate the separation of patients who were early responders from the subjects who were not.
Replication study of antipsychotic effects (study II)
A replication study on 23 new patients with schizophrenia shows that metabolic changes were, to a large extent, similar to what we noted with study I (Figure 2) , however, this study had a smaller number of patients treated with olanzapine and risperidone, and hence, a lower statistical power and significance. The average number of days of treatment was similar for all Figure 3 Change detection plot. Change detection was used to determine if observed signals in lipids from the antipsychotic-treated subjects were greater than that which could be expected by chance. The gray shaded area represents the number of P-values that would be expected by chance or noise in the data. The P-values for posttreatment of each drug are plotted with aripiprazole in yellow, risperidone in red and olanzapine in blue. The rankings of the P-values for both olanzapine and risperidone were above that expected by chance.
antipsychotics in this replication study to partially control for possible differences due to shorter treatment length with aripiprazole in study I.
Olanzapine-treated subjects had significantly increased concentrations of PC, PE and TG (Figure 2a  and b) , however, the small sample size and shorter drug-treatment time may have prevented many of the lipid changes from reaching significance. As was seen in the first study, FAs also decreased significantly with olanzapine treatment in study II (P = 0.02). In addition, there were increases in many of the fatty acid metabolites of PE and PC, but no change in the concentration of PC20:4n6 or PE20:4n6 as noted in study I (Figures 1 and 2 ). The ratio 20:4n6/ 20:3n6 also decreased in CE, PE and PC (data not shown) as was noted in study I but did not reach significance.
Treatment with risperidone resulted in significantly increased TG and DG concentrations (Figure 2c-f) with specific fatty acid changes within each lipid class. The concentrations of PC and PE also increased, but only reached a significance of 0.14 and 0.16. As with the first study, PC18:3n6, PC20:2n6 and PC20:3n6 concentrations increased (P = 0.029, 0.098, 0.090) while the concentration of PC20:4n6 (AA) did not change (Figure 2) .
Even with the larger sample set, minimal lipid changes were seen in patients with aripiprazole treatment in the replication set (Figure 2g-h) , which was consistent with the study I findings. PE concentration increased, but this change did not reach statistical significance. No significant changes were found with the other lipid classes and very little change was seen in the fatty acid concentrations.
Analysis of lipid pathways for drug effects
To characterize fatty acid elongation and desaturation processes that might be modified in schizophrenia compared with control subjects, various ratios of products to substrates in different fatty acid pathways were determined and are summarized in Supplementary Table 3 . Following the treatment with olanzapine or risperidone, the alterations of fatty acid ratios in patients with schizophrenia (Supplementary Table 3) were essentially reversed toward normal ranges by these atypical antipsychotic drugs. In brief, the ratios 
Discussion
The study of metabolism at the global or '-omics' level is a new but rapidly growing field that has the potential to impact medical practice at many levels. 33 The metabolic state of an individual reflects what has been encoded by the genome and modified by environmental factors an 'environment' that -in the clinical setting -includes drug exposure. 34, 35 A deeper understanding of global perturbations in biochemical pathways in complex diseases such as schizophrenia and upon treatment with antipsychotics could provide valuable insights about mechanisms of disease, drug effects and biomarkers. 35 Holmes et al. 36 used an NMR-based metabolomics platform to evaluate a subset of pathways implicated in intermediary metabolism and established that glucose and acetate were modified in cerebrospinal fluid of patients with schizophrenia. The findings reported here represent to our knowledge, a first attempt to map global lipid changes in schizophrenia before and after treatment with three antipsychotics using a specialized metabolomics platform referred to as lipidomics.
Phospholipid alterations in schizophrenia
We derived an initial and preliminary lipidomic signature for schizophrenia that attempts to capture global changes within fatty acids in seven lipid subclasses. The study confirms that significantly lower levels of plasma PE are found in patients with schizophrenia when compared with normal controls. A detailed analysis within the PE class reveals that, Principle component analysis for CGI change variable. Logistic regression was used to identify the pretreatment lipid metabolites that were related to response (responders who had a CGI change score of 1-2 and nonresponders who had a score of 3-6). Principle component analysis was then applied to these metabolites and the separation of the groups was visualized by a scatter plot of the first versus the second principal component. Red squares are subjects who respond to drug treatment with a CGI change score of 1-2. Blue circles are subjects who do not respond to drug treatment with a CGI change score of 3-6. Analysis was conducted as described in the Materials and methods.
the PUFAs (n3, n6 and n9 fatty acid families) and the fatty aldehyde (16:0, 18:0 and 18:1) moieties of plasma PE were all reduced. In addition, PC was slightly downregulated with more significant decrease noted in n3 and n6 fatty acid families. No significant changes were seen within the five other lipid classes. These findings are consistent with and substantially add to the previous reports of decrease in phospholipids in red blood cells (RBC) of psychotic patients 37 and medication-free schizophrenic patients; 38 in fibroblasts from neuroleptic-naïve schizophrenic patients; 39 in platelet membranes of drug-naïve patients with schizophrenia 40 and in post-mortem brain tissue from patients with schizophrenia. 41, 42 There is also convincing evidence for abnormal central phospholipid metabolism in first-episode and chronic schizophrenic patients. 43 In healthy human subjects, brain levels of the phospholipid breakdown product PDE (as assessed via 31 P MRS) also correlate with reduced RBC concentrations of DHA and eicosapentaenoic acid. 44 More recently, Yao et al. 45 has demonstrated that such correlations also occur in peripheral and central phospholipids and PUFA in patients with schizophrenia, suggesting peripheral and central membrane dynamics may be coupled. Taken together, these data suggest that schizophrenia may potentially involve a lipid disorder expressing throughout the whole body. 46 At this early stage, the initial lipidomic signature defined here should not be interpreted as a diagnostic one for schizophrenia. When defining disease signatures as biomarkers for schizophrenia, patients and controls must be very carefully matched; possible confounding effects of other medications and disease states have to be considered, as these could contribute to signatures and biomarker development. Replication and validation studies are needed in independent sets of patients and controls. Hence, this is the first step toward the development of a metabolic signature as a biomarker for schizophrenia. Combined information from different metabolomics platforms could provide a far more robust diagnostic signature. Such studies are currently under way.
Metabolic signatures of antipsychotics
In the present study, the acute effects of three commonly used atypical antipsychotic drugs were investigated after 2-3 weeks treatment. All patients remained hospitalized for the entirety of their participation to minimize confounding factors (e.g. diet, exercise and smoking among other factors) on metabolic signatures. We also excluded patients who were receiving treatment for diabetes mellitus or hyperlipidemia that could interfere with our lipidomics analysis. Each patient is his or her own control as we compared changes in lipidomic profiles (postvs pre-treatment) which adds confidence that changes noted in our heat maps are most probably related to therapy effects.
While there were changes in both n6 and n3 fatty acid families, changes were more pronounced in the n6 than in the n3 fatty acid family following olanzapine and risperidone treatment (Supplementary Table 3 ). Furthermore, olanzapine appears to be more potent than risperidone in modification of plasma phospholipids (Figures 1 and 5 ). On the other hand, plasma fatty acid compositions were affected minimally in patients after treatment with aripiprazole (Figure 1b) .
Possible mechanisms involving altered PUFAs pathways
Arachidonic acid (AA) [20:4n6] is mainly synthesized from linoleic acid [18:2n6] by desaturation and elongation ( Figure 5 ). Linoleic acid, a so-called essential fatty acid, cannot be synthesized by mammals and must be obtained from dietary plant sources. A deficiency of linoleic acid usually leads to a higher content of n9 trienoic acids, which can be synthesized endogenously. 47 An increased level of plasma 20:3n9 was not demonstrated either in the present study or other schizophrenic patient groups. 48, 49 Lack of increased level 20:3n9 was also found in RBC ghost membranes of patients with chronic schizophrenia on and off antipsychotic treatment. 50 It is thus reasonable 
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PE a b Figure 5 The regulation of pathways for biosynthesis of PC n-6 fatty acids in schizophrenic patients post-treatment as compared to pretreatment with (a) olanzapine and (b) risperidone. The activities of each of the enzymes were estimated utilizing the ratios of fatty acids (products and reactants) as indicated in the Materials and methods with significant increases indicated in red and decreases indicated in green. Data on ratios of metabolites are shown in Supplementary Table 1. to exclude a dietary deficiency of linoleic acid in our patients with schizophrenia. The major n6 pathway consists of a series of desaturation (D6 and D5 reactions) and elongations ( Figure 5 ). In normal plasma, the levels of 18:3n6 and 22:5n6 are very small, with 20:4n6 as the major metabolic product of 18:2n6. Decreased ratios of 20:3n6/20:2n6 and 20:2n6/18:2n6 (Supplementary  Table 3 ) suggest a defect in the conversion of 18:2n6 to 20:3n6 in patients with schizophrenia. The decreased level of 20:3n6 may lead to an increased ratio of 20:4n6/20:3n6 with a normal or possibly increased D5 desaturase.
Following the treatment with olanzapine or risperidone, Figure 5 highlights the regulation of pathways for biosynthesis of n6 PUFAs in PC and PE that illustrates the possible increase of D6 desaturase and decrease of D5 desaturase in patients with schizophrenia.
The decreased ratio of 18:0/16:0, but not 24:0/22:0 (Supplementary Table 3 ), indicates that chain elongation (i.e. 18:0) was significantly less in patients with schizophrenia than in the normal control subjects. Such a reduction in 18:0 in patients with schizophrenia was essentially reversed after the treatment with risperidone or olanzapine (Figure 1) . A decreased ratio of 18:0/16:0 was also found in RBC ghost membrane lipids from patients with chronic schizophrenia off-haloperidol treatment. 50 However, haloperidol treatment had little effect on RBC membrane fatty acid levels.
Events possibly related to metabolic side effects There was also a marked decrease in FAs accompanied by an increase in TG pointing to possible effects on lipases (LPL, HSL) involved in storage and release of TG and FAs from adipose tissue. The decrease in FAs may be an effect of the drug reducing lipase activity and fatty acid mobilization. Decreased fatty acid release from adipose tissue together with the increased hepatic lipid synthesis could be responsible for the hyperlipidemia and lead to weight gain over time. Following the olanzapine or risperidone treatment, the increased triacylglycerol and phospholipid content of the plasma suggests the increased presence of very low-density lipoproteins.
In addition, the increased cholesterol with olanzapine treatment suggests a potential increase in lowdensity lipoprotein content. For olanzapine, the increased concentrations of 16:1n7, 18:1n7 and 18:1n9 suggest an increase in fatty acid synthesis. There is less evidence for an increase in fatty acid synthesis in the risperidone-treated subjects. Increase in fatty acid biosynthesis upon treatment with several antipsychotic and antidepressant drugs has been noted before in cell culture assay systems implicating a transcription factor in the mechanism of action of these drugs. 51, 52 Replication of findings Generally, similar findings emerged between the two data sets (Figure 2 ) although the second study was a week shorter. We had fewer subjects on olanzapine and risperidone in set II that could have impacted the statistical significance of some of the findings but not the trends. These data suggest a rapid onset of antipsychotic drug effects on specific plasma lipidome. Interestingly, aripiprazole-treated patients had remarkably few changes in plasma lipid metabolites, which was replicated in the second set of larger sample size. While the drug was given for a shorter length of time than olanzapine in the first study, all drugs were given for 2 weeks in the second study and our findings are consistent between study I and II indicating far less lipid changes with aripiprazole. It is possible that aripiprazole may (probably does not) regulate the same lipid pathways as olanzapine and risperidone.
Antipsychotic drug effects
To evaluate which of the lipid changes noted in response to antipsychotics are related to metabolic side effects or to therapeutic benefit requires larger sample sets and longitudinal studies. The common effects of the three drugs on PE might suggest that this is related to their therapeutic benefit. On the other hand, the effects on FAs and TG that were associated with olanzapine and risperidone but not with aripiprazole could be related to metabolic side effects seen with these drugs. Using a logistic regression, a set of baseline lipid metabolites was found that could separate responders from nonresponders (DG20:4n6, LY22:5n3, PE20:5n3, PEdm18:1n7, PEdm18:1n9). However, these are very low-abundance metabolites and such findings need to be interpreted with caution and validated in larger patient populations before one can determine their predictive power. A future study would be to use a larger cohort of subjects and identify prognostic markers specific for each drug as well as those markers which are common for the class. Such studies could potentially contribute to better optimization of therapy for a given patient and better prognostic prediction of outcomes. Currently, noncompliance for side effects and nonresponse is a major limitation of long-term effectiveness in clinical practice, and metabolomics may be a promising tool for identifying additional markers of response and nonresponse, that is, pharmacometabolomics. In summary, a larger prospective study examining metabolomic patterns of the first-episode patients with schizophrenia before and after random assignment to various antipsychotic drugs may be timely to build on these initial findings.
Limitations and strengths
Our results have to be interpreted with caution due to the following limitations: (1) Our sample size was relatively small regardless of the enormous effort and expense involved in analyzing more than 300 metabolites in each subject. (2) Matching of patients and controls should take into consideration the other factors than age, gender and race for deriving disease signatures and nonhospitalized patients should be included in the future studies. Close monitoring of diet and exercise and the possible confounding effects of other medications and disease states has to be considered. Ideally, more than one site should be used for the recruitment of patients and controls. These are less of an issue for deriving drug signatures where each patient acts as his or her own control. (3) Our treatment assignment was not randomized and while there was no systematic plan for which patient would get which drug, subtle biases cannot be excluded hence future randomized studies are needed to derive conclusions specific for each drug. (4) Treatment duration was, generally, too short to study clinical correlations fully and treatment duration was minimally shorter for aripiprazole-treated patients than for the other groups in one of the studies. Longitudinal studies are needed to confirm and expand on these initial findings. (5) Selected drug doses were based on what is most commonly used by clinicians today yet higher doses for aripiprazole that are used by some clinicians were not explored. Higher doses of aripiprazole and extended use might start to unravel lipid changes. (6) In this study, we only explored newer atypical antipsychotics and it is important to include oldergeneration typical antipsychotics in future studies. (7) Future trials should be designed to determine lipids that correlate with clinical outcome for each drug. (8) There were multiple comparisons in our studies. Hence, our findings are best viewed as hypotheses generating rather than as definitive conclusions. As such, this is the first metabolomic study to document patterns of lipid changes across seven major classes in schizophrenia before and after therapy with three commonly used atypical antipsychotic drugs. The use of a replication sample set adds strength to the findings demonstrating a rapid onset of drug-specific metabolomic effects. Our initial findings raise the need for a longer-term prospective study examining lipidomic changes in schizophrenia before and after random assignment to various antipsychotic drugs and the clinical correlates of lipid alterations. Such a study has the potential to increase our knowledge of the clinical consequences of lipid changes induced by treatments and yield potential markers that may help with patient monitoring and drug development.
